Roundhill introduced the Space & Technology ETF (MARS), targeting companies with over half their revenue from space-related activities. The ETF offers concentrated exposure to civil, commercial, and defense space sectors, benefiting from rising investments in satellite communications, lunar missions, and space infrastructure, notably driven by NASA's Artemis program. MARS is actively managed with a 0.75% expense ratio and is suited for long-term investors seeking diversified exposure to the growing space economy. However, its low assets under management and manager risk should be considered by investors.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Telix Pharmaceuticals and Ekalia have teamed up to establish U.S.-based production of astatine-211, a rare alpha-emitting isotope used in targeted alpha therapy for cancer. This collaboration combines IBA's cyclotron technology, Framatome's nuclear e...
Ekalia, a joint venture between IBA and Framatome, has partnered with Telix Pharmaceuticals to accelerate the production of Astatine-211, a promising alpha-emitting radioisotope used in targeted cancer therapies, in the United States. The collaborati...
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
